Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity

Surgery for Obesity and Related Diseases

Volumn 4, Issue 6, 2008, Pages 748-753

  Barletta, Jeffrey F ^a   DeYoung, Jaculin L ^a   McAllen, Karen ^a   Baker, Randal ^a   Pendleton, Kevin ^b  

^a Spectrum Health ^*  (United States)

^b Northern Michigan Hospital   (United States)

Author keywords

Dosing; Heparin; Nomogram; Obesity

Indexed keywords

HEPARIN;

ADULT; AGE; ANTICOAGULATION; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORBID OBESITY; NOMOGRAM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STANDARDIZATION;

ANALYSIS OF VARIANCE; ANTICOAGULANTS; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; HEPARIN; HUMANS; NOMOGRAMS; OBESITY, MORBID; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 56049127927     PISSN: 15507289     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soard.2008.03.005     Document Type: Article

References (20)

1. Nasraway S.A., Albert M., Donnelly A.M., Ruthazer R., Shikora S.A., and Saltzman E. Morbid obesity is an independent determinant of death among surgical critically ill patients. Crit Care Med 34 (2006) 964-970
2. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
3. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
4. Pieracci F.M., Barie P.S., and Pomp A. Critical care of the bariatric patient. Crit Care Med 34 (2006) 1796-1804
5. Hirsh J., and Raschke R.A. Heparin and low molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
6. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity (1998), World Health Organization, Geneva
7. Cippole R.J., and Rodvold K.A. Heparin. In: Evans W.E., Schentag J.J., and Jusko W.J. (Eds). Applied pharmacokinetics: principles of therapeutic drug monitoring (1992), Applied Therapeutics, Vancouver, WA p. 30-1-39
8. Raschke R.A., Reilly B.M., Guidry J.R., Fontana J.R., and Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 119 (1993) 874-881
9. Yee W.P., and Norton L.L. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 55 (1998) 159-162
10. Spruill W.J., Wade W.E., Huckaby W.G., and Leslie R.B. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm 58 (2001) 2143-2146
11. Hull R.D., Raskob G.E., and Rosenbloom D. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 152 (1992) 1589-1595
12. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 39 (2000) 215-231
13. Gallagher D., Visser M., Sepulveda D., Pierson R.N., Harris T., and Heymsfield S.B. How useful is body mass index for comparison of body fatness across age, sex and ethnic groups?. Am J Epidemiol 143 (1996) 228-239
14. Green B., and Duffull S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol 58 (2004) 119-133
15. Fernandez J.R., Heo M., Heymsfield S.B., et al. Is percentage body fat differentially related to body mass index in Hispanic Americans, African Americans and European Americans?. Am J Clin Nutr 77 (2003) 71-75
16. Ellison M.J., Sawyer W.T., and Mills T.C. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 8 (1989) 65-68
17. Rosborough T.K. In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone. Pharmacotherapy 18 (1998) 1217-1223
18. Rosborough T.K., and Shepherd M.F. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height and weight. Pharmacotherapy 24 (2004) 713-719
19. Levine M.N., Raskob G., Beyth R., et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 287-310
20. Calabrese A.D., Erstad B.L., Brandl K., Barletta J.F., Kane S.L., and Sherman D.S. Medication administration errors in adult patients in the ICU. Intens Care Med 27 (2001) 1592-1598